NMDA receptor antagonists acting at the glycine(B) site in rat models for antipsychotic-like activity

Journal of Neural Transmission

Volumn 106, Issue 11-12, 1999, Pages 1189-1204

  Karcz Kubicha, M ^a   Wedzony, K ^b   Zajaczkowski, W ^b   Danysz, W ^a,b  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Amphetamine; Antipsychotics; Glycine(B) antagonists; L 701,324; MRZ 2 576; NMDA antagonists; Phencyclidine; Prepulse inhibition

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; AMPHETAMINE; GLYCINE; GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PARTIAL AGONIST; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; STARTLE REFLEX;

2-AMINO-5-PHOSPHONOVALERATE; AMPHETAMINE; ANIMALS; ANTIMETABOLITES; ANTIPSYCHOTIC AGENTS; BINDING SITES; CYCLOLEUCINE; CYCLOSERINE; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HALLUCINOGENS; LOCOMOTION; MALE; PHENCYCLIDINE; PHTHALAZINES; PROTEIN STRUCTURE, TERTIARY; PSYCHOTIC DISORDERS; PYRROLIDINONES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; STARTLE REACTION;

EID: 0033460316     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050233     Document Type: Article

References (42)

1. AparicioLegarza MI, Cutts AJ, Davis B, Reynolds GP (1997) Deficits of [H-3]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci Lett 232: 13-16
2. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794
3. Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL, Li H, Weber E (1995) Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 6: 577-589
4. Baron BM, Harrison BL, Kehne JH, Schmidt CJ, VanGiersbergen PLM, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG (1997) Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol 323: 181-192
5. Bristow LJ, Landon L, Saywell KL, Tricklebank MD (1995) The glycine/NMDA receptor antagonist, 1-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology 118: 230-232
6. Bristow LJ, Flatman KL, Hutson PH, Kulagowski JJ, Leeson PD, Young L, Tricklebank MD (1996) The atypical neuroleptic profile of the glycine/n-methyl-d-aspartate receptor antagonist, 1-701,324, in rodents. J Pharmacol Exp Ther 277: 578-585
7. Bristow LJ, Hutson PH, Kulagowski JJ, Leeson PD, Matheson S, Murray F, Rathbone D, Saywell KL, Thorn L, Watt AP, Tricklebank MD (1996) Anticonvulsant and behavioral profile of 1-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther 279: 492-501
8. Carlsson M, Carlsson A (1990) Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272-276
9. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994) D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia - an open-label study. J Neural Transm [Gen Sect] 95: 105-111
10. Contreras PC (1990) D-Serine antagonized phencyclidine-induced and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 29: 291-293
11. Danysz W, Parsons CG (1998) Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50: 597-664
12. Danysz W, Essmann U, Bresink I, Wilke R (1994) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48: 111-118
13. Danysz W, Parsons C, Karcz-Kubicha M, Gold M, Kalvinch I, Piskunova I, Rozhkov E (1996) Novel systemically active antagonists of the glycine site of NMDA receptor - behavioural characterisation. Soc Neurosci Abstr 22: 1530
14. Deutsch SI, Huntzinger JA, Rosse RB, Kaushik M, Mastropaolo J (1989) The role of excitatory amino acids and intraneuronal calcium in the acute intoxicational effects of ethanol. Clin Neuropharmacol 12: 483-489
15. Furuya Y, Ogura H (1997) Competitive NMDA and strychnine-insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol Biochem Behav 57: 909-913
16. Furuya Y, Kagaya T, Nishizawa Y, Ogura H (1996) An antagonist at the strychnine-insensitive glycine site differentially affects hyperactivity and the disruption of prepulse inhibition (PPI) induced by phencyclidine. Soc Neurosci Abstr 22: 1530
17. Gandolfi O, Dallolio R (1993) Chronic treatment with MK-801 decreases d2 dopamine receptor function in rat striatum. Pharmacol Biochem Behav 44: 683-687
18. Goff DC, Tsai GC, Manoach DS, Coyle JT (1995) Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152: 1213-1215
19. B-site: microdialysis and MES studies. J Pharmacol Exp Ther (in press)
20. Humphries C, Mortimer A, Hirsch S, Debelleroche J (1996) NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7: 2051-2055
21. Hutson PH, Bristow LJ, Thorn L, Tricklebank MD (1991) R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmacol 103: 2037-2044
22. Hutson PH, Thorn L, Bristow LJ, Tricklebank MD (1995) L-701,324, a glycine/NMDA receptor antagonist, attenuates activation of the mesolimbic dopamine system by phencyclidine. Br J Pharmacol 114: 322P
23. Ishimaru MJ, Toru M (1997) The glutamate hypothesis of schizophrenia: therapeutic implications. CNS Drugs 7: 47-67
24. Javitt DC (1996) Glycine therapy of schizophrenia. Biol Psychiatry 40: 684-685
25. Javitt DC, Frusciante M (1997) Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology 129: 96-98
26. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
27. B antagonists and partial agonists in rodent models of Parkinson's disease - comparison with uncompetitive NMDA receptor antagonists. Neuropharmacology 38: 109-119
28. Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30: 557-566
29. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmiller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379-382
30. Kretschmer BD, Kratzer U, Breithecker K, Koch M (1997) ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. Eur J Pharmacol 331: 109-116
31. Krueger JM, O'Connor AJ, Kelso SR (1997) Glycine site agonists exhibit subunit specificeffects on NMDA receptors expressed in Xenopus oocytes. Soc Neurosci Abstr 23: 945
32. Luby ED, Cohen RC, Rosenbaum B, Gottlieb JS, Kelly R (1959) Study of a new schizophrenomimetic drug: Sernyl. Arch Neurol Psychiat 81: 363-369
33. Muir KW, Grosset DG, Gamzu E, Lees KR (1994) Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 38: 33-38
34. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM (1997) Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283: 1264-1275
35. Sveinbjornsdottir S, Sander JWAS, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS (1993) The excitatory amino acid antagonist d-CPP-ene (sdz eaa-494) in patients with epilepsy. Epilepsy Res 16: 165-174
36. Swerdllow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficit sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51: 139-154
37. Tallarida RJ (1992) Statistical analysis of drug combinations for synergism. Pain 49: 93-97
38. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1994) Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 269: 1040-1048
39. Varty GB, Higgins GA (1995) Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol 287: 201-205
40. Wan FJ, Geyer MA, Swerdlow NR (1995) Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology 120: 433-441
41. Waziri R (1988) Glycine therapy of schizophrenia. Biol Psychiatry 23: 209-214
42. Wedzony K, Golembiowska K, Zazula M (1994) Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol 350: 555-562